Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Revelation Biosciences Inc
REVB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.79
0.11
2.99%
Ult. Agg.: Oct 21, 4:54 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Frazionamento azionario:
Si prevede che Revelation Biosciences Inc effettuerà lo split Tuesday, October 20, 2026 con un rapporto di 1:7
Revelation Biosciences Financials
Revelation Biosciences (REVB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses of $(7.01) per share
Benzinga Newsdesk
PRO
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
Benzinga Newsdesk
PRO
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over losses of $(59.76) per
Benzinga Newsdesk
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP exceeds estimates.
Vishaal Sanjay
PRO
Revelation Biosciences Q3 EPS $(1.77) Misses $(1.33) Estimate
Benzinga Newsdesk
PRO
Revelation Biosciences Q2 EPS $(7.01) Misses $(1.49) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate of $(1.49) by 372.05 percent. This is a 97.15 percent increase over losses of $(246.24) per
Benzinga Newsdesk
